Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 12,277 shares at $130.58 ($1.6M) on 2018-12-10, disclosed to the SEC on 2018-12-12.
Open-market sale of $1.6M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.58 | 969 | $127K | 7.7% |
| 2 | $132.09 | 2,001 | $264K | 16.1% |
| 3 | $133.00 | 2,104 | $280K | 17.0% |
| 4 | $134.31 | 2,049 | $275K | 16.8% |
| 5 | $135.04 | 2,377 | $321K | 19.5% |
| 6 | $135.04 | 2,377 |
| $321K |
| 19.5% |
| 7 | $136.48 | 400 | $55K | 3.3% |
| Total | $133.78 avg | 12,277 | $1.6M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $915K | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |